Kornimate/medical-research-clean huggingface dataset:
study of cytokine-induced killer cell (cik) treatment in patients after resection of liver cancer

Conditions: Hepatocellular Carcinoma

Summary: study hypothesis: the recurrence rate of hcc patients after radical resection is about 60-70%. this study is based on the hypothesis that cik treatment could decrease the recurrence rate by 15% to 20%. abstract: this is a randomized controlled study. about 200 patients with hepatocellular carcinoma who underwent radical resection will be included. the patients will be randomized to group a (receive cik treatment) or group b (just regularly follow up) without any anti-cancer treatment after resection of hcc, and the randomize ratio will be 1:1. study treatment: patients in group a will receive 4 cycles of cik treatments within 3 months after their liver resection. patients in group b will have no anti-cancer therapy. anti-virus and other supportive therapies are available in both groups.


Eligibility criteria:
inclusion criteria * male or female patients \> 18 years of age. * without any prior anti-cancer therapy. * patients who have a life expectancy of at least 12 weeks. * patients already had radical resection of hcc. * definition of radical resection in this study: * all tumors were moved out, with a clean resection margin. * number of tumors \<= 3. * without tumor invasion of the main trunk and first branch of the portal vein, or hepatic duct, or hepatic vein. * no hepatic hilum lymphnode metastasis. * no distance metastasis. * hepatocellular carcinoma with histological diagnose. * no major post-operative complication. * patients who have an ecog ps of 0, or 1. * cirrhotic status of child-pugh class a only. * the following laboratory parameters: * platelet count \>= 70 x 109/l * hemoglobin \>= 8.5 g/dl * albumin \>= 3.5 g/dl * total bilirubin \<= 25umol/l * alanine transaminase (alt) and ast \<= 2.5 x upper limit of normal * serum creatinine \<= 1.5 x the upper limit of normal * prothrombin time (pt) \<= 3 seconds above control. * patients who give written informed consent. exclusion criteria * previous or concurrent cancer that is distinct in primary site or histology from hcc. * history of cardiac disease. * active clinically serious infections (\> grade 2 national cancer institute \[nci\]-common terminology criteria for adverse events \[ctcae\] version 3.0) * known history of human immunodeficiency virus (hiv) infection * known central nervous system tumors including metastatic brain disease. * patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry. * history of organ allograft. * known or suspected allergy to the investigational agent or any agent given in association with this trial. * pregnant or breast-feeding patients. * any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study. excluded therapies and medications, previous and concomitant: * prior use of any anti-cancer treatment for hcc, eg. chemotherapy, radiotherapy. * antiviral treatment is allowed.

Keywords: hepatocellular carcinoma recurrent cytokine-induced killer cell
a multicenter study comparing the safety and efficacy of abt-335 and rosuvastatin calcium combination therapy to monotherapy in subjects with dyslipidemia

Conditions: Hypercholesterolemia; Dyslipidemia

Summary: the purpose of this study is to evaluate the safety and efficacy of abt-335 and rosuvastatin calcium combination therapy to monotherapy in subjects with dyslipidemia.

there are 3 treatment groups in the study: abt-335 135 mg in combination with rosuvastatin 5 mg, abt-335 135 mg monotherapy, and rosuvastatin 5 mg monotherapy. the 3 primary outcome measures only compare 2 of the treatment groups for each variable (mean percent change in hdl-c and tg comparing abt-335 135 mg in combination with rosuvastatin 5 mg to rosuvastatin 5 mg monotherapy, and mean percent change in ldl-c comparing abt-335 135 mg in combination with rosuvastatin 5 mg to abt-335 135 mg monotherapy. the 6 secondary outcome measures only compare 2 of the treatment groups for each variable (mean percent change in non-hdl-c comparing abt-335 135 mg in combination with rosuvastatin 5 mg to abt-335 135 mg monotherapy, mean percent change in non-hdl-c, vldl-c, apob, and total cholesterol comparing abt-335 135 mg in combination with rosuvastatin 5 mg to rosuvastatin 5 mg monotherapy, and median percent change in hscrp comparing abt-335 135 mg in combination with rosuvastatin 5 mg to rosuvastatin 5 mg monotherapy).

Eligibility criteria:
inclusion criteria * adult male and female participants who voluntarily sign the informed consent. * fasting lipid results following greater than 12-hour fasting period: * triglycerides level greater than or equal to 150 mg/dl, * high-density lipoprotein cholesterol less than 40 mg/dl for males and less than 50 mg/dl for females, and * low-density lipoprotein cholesterol greater than or equal to 130 mg/dl. * participant must agree to utilize adequate birth control methods and adhere to the american heart association (aha) diet. exclusion criteria * participants with unstable medical conditions, medical conditions considered inappropriate in a clinical trial, or participants who are taking excluded concomitant medications are not allowed in the study. * participants receiving coumarin anticoagulants or systemic cyclosporine.
cleveland clinic families get fit (ccfit) : a family-based activity-monitor intervention in pediatric obesity

Conditions: Obesity, Childhood

Summary: this is a randomized prospective study to evaluate the effectiveness of a family-based intervention using activity-monitors (i.e. fitbits) in children and adolescents aged 8-18 years with a bmi greater than or equal to 95%ile who attend the cleveland clinic multidisciplinary "be well" pediatric obesity clinic.


Eligibility criteria:
inclusion criteria: * be well patient * age 8\*-18 years * bmi \> 95%ile * english speaking exclusion criteria: * uncontrolled asthma * orthopedic or other medical issue limiting mobility * participant has worn an activity-monitor in the past 6 months (ok if parents wear)
evaluating treatable traits across the spectrum of chronic obstructive airways disease

Conditions: Airway Disease

Summary: respiratory disease affects one in five people and is a leading cause of global morbidity and mortality. chronic obstructive airways diseases encompass conditions characterised by expiratory airflow limitation, exertional dyspnoea, activity limitation and impaired quality of life. the most common conditions include chronic obstructive pulmonary disease (copd), asthma, bronchiectasis, cystic fibrosis and primary ciliary dyskinesia. in recent years, there has been concerted effort in the scientific and respiratory medicine community to improve the diagnosis and management of chronic obstructive airways diseases using personalised or precision medicine (i.e., tailoring therapies and interventions according to specific "treatable traits") and identifying phenotypes or endotypes using validated biomarkers. to date, however, research in this setting has primarily focussed on people with copd and asthma, with limited studies in other forms of chronic obstructive airways diseases. the aim of this study is therefore two-fold; first, to compare pulmonary physiology (i.e., large and small airway involvement) and extra-pulmonary manifestations across the spectrum of chronic obstructive airways, and second, to determine how disease-specific treatable traits associate with physical activity and health-related quality of life.


Eligibility criteria:
inclusion criteria: * prior diagnosis of airways disease in accordance with european respiratory society guidelines. * non / ex-smokers (packs recorded as cigarettes per day / years smoked). * male or female aged 18-65 years * ability to provide written informed consent. * full comprehension of spoken and written english language. * cystic fibrosis patients on triple cftr modulators (90% cohort) * cystic fibrosis patients on no cftr modulators * healthy controls - entirely asymptomatic, no prior history of inhaler medication use and free from respiratory disease. exclusion criteria: * severe exacerbation requiring hospital admission or oral corticosteroids (ocs) in the past two months. * absolute or relative contraindications to cardio-pulmonary exercise testing or submaximal exercise testing. * absolute or relative contraindications to pulmonary function testing . * absolute or relative contraindications to dual energy x-ray (dexa) scanning (i.e., pregnancy, recent contrast media administration or subject weight). * non-ambulant or musculoskeletal impairment that may affect activities of daily living or maximal exercise testing. * significant cognitive impairment (i.e., unable to provide written informed consent or safely / successfully perform tests). * currently receiving oxygen therapy. * inability to consent. * burkholderia cepacia complex, mycobacterium tuberculosis or mycobacterium abseccus infection. * lung transplantation * diagnosis of cardiovascular disease. * abnormal blood screening (anaemia, moderate / severe renal failure etc.)
echocardiographic and laboratory findings in hemodynamic monitoring of shocked patients

Conditions: Shock

Summary: shocked patients require prompt and accurate assessment of their hemodynamic status to guide appropriate management. echocardiography is a valuable tool for assessing cardiac function, while laboratory parameters such as mixed venous oxygen saturation and arterial blood lactate provide insights into tissue perfusion and oxygen metabolism. this study aims to compare echocardiographic findings, including cardiac index, speckle tracking parameters, and tissue doppler indices, with laboratory findings in the evaluation of hemodynamic monitoring in shocked patients.

shocked individuals necessitate expeditious and precise evaluation of their hemodynamic condition to direct appropriate treatment. the utilization of echocardiography is an invaluable method for appraising cardiac function, while the inclusion of laboratory parameters such as mixed venous oxygen saturation and arterial blood lactate offers valuable insights into tissue perfusion and oxygen metabolism. the primary objective of this study is to compare the echocardiographic discoveries, which encompass the assessment of cardiac index, speckle tracking parameters, and tissue doppler indices, with the laboratory findings in the comprehensive assessment of hemodynamic monitoring in individuals experiencing shock. the purpose of this investigation is to delineate the correlation between echocardiographic and laboratory assessments in order to enhance our understanding of hemodynamic status in patients who are in a state of shock.

Eligibility criteria:
inclusion criteria: * patients diagnosed with shock based on clinical criteria (e.g., hypotension, signs of tissue hypoperfusion) requiring hemodynamic monitoring. * patients age \> 18 year old. exclusion criteria: * patients with pre-existing cardiac conditions affecting echocardiographic parameters, those receiving mechanical circulatory support. * patients with contraindications to echocardiography or blood sampling.
a prospective, randomized, placebo and active comparator controlled study of cp-690,550 in subjects with dry eye.

Conditions: Dry Eye Syndromes

Summary: a prospective, randomized, placebo and active comparator controlled study of cp-690,550 in subjects with dry eye.


Eligibility criteria:
inclusion criteria: * symptoms of dry eye for at least 6 months. * signs of moderate to severe dry eye exclusion criteria: * women who are nursing or pregnant * participation in other studies within 30 days of screening visit * ocular disorders that may confound interpretation of study results

Keywords: dry eye
correlation between the change of peripheral lymphocyte subsets and clinically amyopathic dermatomyositis combined with rapidly progressive interstitial lung disease

Conditions: Clinically Amyopathic Dermatomyisitis(CAMD)

Summary: acute respiratory distress syndrome (ards) occurs in clinically amyopathic dermatomyisitis(cadm) combined with rapidly progressive interstitial lung disease(rpild) within 1-3 months, which leads to death of patients and is difficult to treat. even if high doses of glucocorticoids are ineffective, there is no recommended treatment for such patients, which is a huge medical challenge.lymphopenia is an independent risk factor for death in cadm-rpild, but the cause of lymphopenia is unclear.in this study, the level of lymphocyte subsets in peripheral blood was detected by flow cytometer, in order to further clarify the pathogenesis of the disease, to facilitate clinical guidance of treatment, and to improve the survival rate of patients.in addition, studies have shown that inf-α levels are significantly increased in cadm patients combined with rpild and are a poor prognostic factor for cadm-rpild, suggesting that the interferon system plays a role in the pathogenesis of cadm and can be used as an evaluation index of the severity of cadm-rpild.in this study, the levels of relevant cytokines including inf and il-2, il-17, il-18, il-6 were detected simultaneously, and the relationship between disease activity and lymphocyte subsets was analyzed, and the changes of lymphocyte subsets after tofacitinib treatment were determined in order to facilitate clinical guidance of treatment.


Eligibility criteria:
inclusion criteria: 1. age≥18 years old,≤80years old,no gender limit; 2. cadm of diagnosis according to sontheimer diagnostic criteria; 3. combined with rapidly progressive interstitial lung disease exclusion criteria: 1. age\ 80years old; 2. potential malignant tumor
examining genetic influence on response to beta-blocker medications in people with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: beta-blockers are medications used to treat cardiovascular disease (cvd) symptoms, including high blood pressure and chest pain. people with diabetes who receive beta-blockers may experience adverse health effects, but the exact cause of why this happens remains unknown. this study will examine the genetic factors that may influence how atenolol, a beta-blocker medication, affects fat breakdown, blood sugar levels, and heart function in people with type 2 diabetes.

people with diabetes who develop cvd have worse health outcomes than people without diabetes who develop cvd. beta-blockers are medications used to treat high blood pressure, angina (i.e., chest pain), arrhythmias, and other cvd conditions. while beta-blockers are effective at treating these conditions, they may also have damaging effects on cholesterol or glucose levels, thereby possibly lessening their ability to prevent cvd events in people with diabetes. it is important to identify which patients may not benefit from receiving beta-blocker medications. genetic factors may influence how people respond to beta-blocker medications. the purpose of this study is to evaluate the influence of genetic variation on beta-blocker-induced changes in insulin sensitivity, fat breakdown, and heart function in people with type 2 diabetes. this study will enroll people with type 2 diabetes. at a series of up to three baseline study visits, participants will have a blood collection, a glucose tolerance test, an echocardiogram to obtain images of the heart, and biopsies of muscle from the thigh and fat from the stomach. all participants will then receive atenolol once a day for 8 weeks. during week 1, participants will receive a low dose of atenolol. they will then attend a study visit at the end of week 1, and study researchers will examine how well participants are tolerating the medication. if the atenolol is well tolerated, the dose will be increased. study researchers will call participants 1 week after any dosage changes to monitor for side effects. blood collection will occur again at a study visit at week 4. at week 8, participants will then attend up to three study visits for repeat baseline testing. participants will then be slowly tapered off of atenolol over a 1-week period.

Eligibility criteria:
inclusion criteria: * type 2 diabetes * pre-diabetes exclusion criteria: * insulin therapy * treatment with any beta-blocker in the 30 days before study entry * asthma * chronic obstructive pulmonary disease (copd) * greater than first degree heart block * heart rate less than 60 bpm * systolic blood pressure less than 90 mm hg * raynaud's phenomenon * known history of angina, heart attack, heart failure, coronary revascularization, or automatic implantable cardioverter defibrillators * pregnant * creatinine clearance less than 35 ml/min * hematologic dysfunction (white blood cell \[wbc\] count less than 3000 or hematocrit less than 28%) * allergy to amide anesthetics

Keywords: diabetes atenolol genetic
a study of jnj-89402638 for metastatic colorectal cancer

Conditions: Unresectable Metastatic Colorectal Cancer

Summary: the purpose of this study is to determine the putative recommended phase 2 dose(s) (rp2ds) of jnj-89402638 and to determine the safety of jnj-89402638 at the rp2d(s) in participants with metastatic colorectal cancer.


Eligibility criteria:
inclusion criteria: * have histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma (crc) progressing after 2 or more prior lines of standard therapy in the metastatic/unresectable setting * have evaluable or measurable disease per response evaluation criteria in solid tumors (recist) version 1.1 1. part 1: must have either measurable or evaluable disease 2. part 2: must have at least 1 measurable lesion * eastern cooperative oncology group (ecog) performance status of 0-1 * have an estimated or measured glomerular filtration rate (gfr) greater than or equal to (\>=) 30 milliliter per minute (ml/min) based on modification of diet in renal disease (mdrd) 4-variable formula exclusion criteria: * active (new or progressive) brain metastases, leptomeningeal disease, or untreated spinal cord compression * toxicity from prior anticancer therapy that has not resolved to grade less than or equal to (\<=)1 (except alopecia, vitiligo, grade \<= 2 peripheral neuropathy, or endocrinopathies that are stable on hormone replacement) * has a prior or concurrent second malignancy (other than the disease under study) unless natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment * received glucocorticoids (doses \>10 mg/day prednisone or equivalent) within 7 days prior to the first dose of study drug * received or plans to receive any live, attenuated vaccine within 4 weeks before the first dose of study treatment or within 4 weeks after the last dose of study treatment
burnout and medical errors in the anaesthesiology fraternity during covid-19 pandemic

Conditions: Burnout, Professional; Depression; Medical Errors; Covid-19

Summary: we plan to perform an observational study to evaluate the prevalence of burnout, depression and medical errors in a designated exclusive covid-19 patients hospital in malaysia, during the covid-19 pandemic. we also seek to assess the relationship between burnout and depression with medical errors. the population studied will be the anaesthesiology fraternity, who are at higher risk to the nature of their work at the frontlines of the pandemic.

during this unprecedented covid-19 pandemic crisis in the whole world, malaysia is also affected, with more than 5000 patients infected in the whole country as of 20th april, 2020. many anaesthesiology clinicians, who are at the frontlines of managing covid-19 patients, face increased workload, in addition to psychological stress from managing these patients, with stress also coming from being exposed to the risk of cross infection. hence, they are possibly at high risk of burnout and depression. in such a time of increased stress, we also seek to find out the prevalence of medical errors by anaesthetic clinicians during this pandemic, and whether the medical errors are associated with burnout. factors associated with burnout, depression and medical errors will also be evaluated.

Eligibility criteria:
inclusion criteria 1. all anaesthesiologists and anaesthesiology medical officers currently serving in the department of anaesthesiology and intensive care, sungai buloh hospital exclusion criteria 1. subjects who refuse to participate 2. subjects working in department of anaesthesiology and intensive care, sungai buloh hospital, for less than 1 month
durability™ iliac study

Conditions: Peripheral Arterial Disease; Claudication

Summary: the durability iliac study is a prospective, multi-center, non-randomized study confirming the safety and effectiveness of stenting using the protégé® everflex™ and protégé® gps™ self-expanding stent systems for the treatment of atherosclerotic lesions in the common and/or external iliac arteries.


Eligibility criteria:
inclusion criteria: * patient has claudication as defined by a rutherford clinical category score of 2, 3 or 4. * evidence of ≥ 50% stenosis, restenosis or occlusion of target lesion(s) located in the common iliac artery and/or external iliac artery. * willing to comply with all follow-up evaluations at the specified times. * provides written informed consent prior to enrollment in the study. exclusion criteria: * previous implantation of stent(s) in the target vessel. * received endovascular treatment of the target lesion within six months prior to the index procedure. * known hypersensitivity to contrast material that cannot be adequately pretreated. * known hypersensitivity to nickel-titanium. * life expectancy of less than 12 months

Keywords: peripheral arterial disease claudication stent everflex gps iliac artery